News >

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

Caroline Seymour
Published: Monday, Jan 14, 2019

Dr. Sumanta Kumar Pal
Sumanta Kumar Pal, MD
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x